IP Library Granted Patent US 9,861,699
Granted Patent B2
US 9,861,699 · App. 14/882,069 · Granted Jan 9, 2018

Pharmaceutical compositions having improved storage stability

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,861,699
App. No.
14/882,069
Granted
Jan 9, 2018
Kind
B2
Abstract

The present invention relates to a pharmaceutical composition that provides long-term stability of a hydrolytically labile antipsychotic agent.

Claims (14)

1. A method for minimizing degradation of a hydrolytically labile antipsychotic agent comprising adding to a composition comprising the antipsychotic agent and an aqueous vehicle (a) a non-ionic water insoluble or immiscible ester co-surfactant and (b) a water miscible or soluble non-ionic surfactant, wherein the antipsychotic agent is Compound 1:

the non-ionic water insoluble or immiscible ester co-surfactant is sorbitan laurate; and

the water miscible or soluble non-ionic surfactant is polysorbate 20.

2. The method of claim 1 , wherein the non-ionic water insoluble or immiscible ester co-surfactant is provided in an amount sufficient to minimize degradation of the antipsychotic agent.

3. The method of claim 2 , wherein the amount of the non-ionic water insoluble or immiscible ester co-surfactant sufficient to minimize degradation is 0.25-0.45 weight percent of the total composition.

4. The method of claim 2 , wherein the amount of the non-ionic water insoluble or immiscible ester co-surfactant sufficient to minimize degradation is 0.3-0.4 weight percent of the total composition.

5. The method of claim 2 , wherein the amount of the non-ionic water insoluble or immiscible ester co-surfactant sufficient to minimize degradation does not exceed 0.5 weight percent of the total composition.

6. The method of claim 2 , wherein the non-ionic water insoluble or immiscible ester co-surfactant is provided in an amount providing less than 50 parts per million of the hydrolyzed antipsychotic agent degradation product after the total composition stands for at least 24 months.

7. The method of claim 2 , wherein the degradation of the hydrolytically labile antipsychotic agent is minimized at temperatures selected from any of 25° C. -40° C., over a time period selected from any of 1 month -24 months.

8. The method of claim 1 , wherein the non-ionic water insoluble or immiscible ester co-surfactant is a sorbitan ester of a carboxylic acid, wherein the carboxylic acid comprises 4-20 carbon atoms.

9. The method of claim 8 , wherein the water miscible or soluble non-ionic surfactant is a polyoxyethylene derivative of a sorbitan ester of a carboxylic acid, wherein the carboxylic acid comprises 8-14 carbon atoms.

10. The method of claim 8 , wherein the sorbitan ester is sorbitan laurate.

11. The method of claim 9 , wherein the polyoxyethylene derivative of a sorbitan ester is polysorbate 20.

12. The method of claim 1 , wherein the hydrolysis product is one of the following compounds:

Assignments (9)
RELEASE OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (073213/0302) Recorded Feb 13, 2026
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 074858/0429 →
SECURITY INTEREST Recorded Feb 13, 2026
From: ALKERMES PHARMA IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 074858/0405 →
SECURITY INTEREST Recorded Oct 23, 2025
From: ALKERMES PHARMA IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 073213/0302 →
RELEASE OF PATENT SECURITY AGREEMENTS Recorded Dec 24, 2024
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 069771/0701 →
SECURITY INTEREST Recorded Mar 20, 2020
From: ALKERMES PHARMA IRELAND LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 052914/0832 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NATURE OF CONVEYANCE FROM ASSIGNMENT TO SECURITY AGREEMENT PREVIOUSLY RECORDED ON REEL 045315 FRAME 0812. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Mar 29, 2018
From: ALKERMES PHARMA IRELAND LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC., AS COLLATERAL AGENT
Reel/Frame 045789/0078 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2018
From: ALKERMES PHARMA IRELAND LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC., AS COLLATERAL AGENT
Reel/Frame 045315/0812 →
SECURITY INTEREST Recorded May 17, 2016
From: ALKERMES PHARMA IRELAND LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 038622/0248 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2015
From: PERRY, JASON M.; DEAVER, DANIEL R.; HICKEY, MAGALI B.; REMENAR, JULIUS F.; VANDIVER, JENNIFER; PALMIERI, MICHAEL J., JR.; PAN, ZHENGZHENG
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 036790/0263 →